20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Gritstone bio Inc (NASDAQ:GRTS) announced that the SARS-CoV-2 T cell epitopes (TCEs) administered within its self-amplifying mRNA (SAM) COVID-19 vaccines are minimally impacted by the Omicron (B.1.1.529) variant.
- Gritstone says that its second-generation SARS-CoV-2 vaccine platform delivers a stabilized Spike protein and highly conserved TCEs derived from other SARS-CoV-2 viral genes, offering potentially more durable protection and broader immunity against the variants.
- Related Link: Gritstone Bio Secures CEPI Funding For Its Differentiated COVID-19 Vaccine Candidate.
- Sequence analysis suggests that Omicron minimally impacts Gritstone's TCEs.
- Specifically, of the 146 non-Spike TCE delivered within Gritstone's vaccine currently in clinical trials in the U.K. and U.S., only 3 (~2%) are impacted by Omicron.
- A similar minimal impact of Omicron is observed in two new vaccine TCE constructs expected to enter clinical trials in South Africa by the end of 2021.
- The Company expects initial clinical data from its U.K. trial in early 2022.
- Price Action: GRTS shares are down 0.52% at $11.05 during the market session on the last check Monday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!